Identification, Characterization and Recent Advances in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: August 27, 2014
Expiration Date: August 27, 2015

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity has been developed to provide clinicians with the most up-to-date information. Pancreatic cancer is a small incidence of malignancy. The majority of community oncology providers will see a few patients with this disease annually. Hence, it is our goal to bring together leading clinicians and researchers from around the country to provide expert perspective in the latest developments across the spectrum of this disease and keeping the viewers of PartnersinPancreaticCancer.com informed and educated. Just seven years from now, pancreatic cancer is projected to become this country’s second leading cancer killer surpassed only by lung cancer and claiming approximately 48,000 lives a year. In today’s activity, we will be covering two spectrums of this disease. The first area we will cover is the identification and characterization of patients and their families who are at increased risk for pancreatic cancer and the latest research being undertaken in this area. We will then look at the recent advances in the treatment of metastatic pancreatic cancer and how these new advances in treatment are being used in the clinical practice setting.

Target Audience

This activity is designed for oncologists, pharmacists, and associated multidisciplinary clinical specialists who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe key ongoing trials that have the potential to impact practice in the near future

  • Summarize recent progress regarding the identification of pancreatic cancer risk factors and the advancement of initial screening to assist in early diagnosis

Agenda

James J. Farrell, MD – Moderator
Jill Lacy, MD – Panelist
Anil Rustgi, MD – Panelist

Instructions for Participation and Credit

This activity is eligible for credit through August 27, 2015. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

James Farrell, MD
Interventional Endoscopy and Pancreatic Diseases
Section of Digestive Diseases
Yale University School of Medicine
New Haven, Connecticut

Dr. James Farrell received his medical degree from University College Dublin. He completed internal medicine training at the Johns Hopkins Hospital and Johns Hopkins University in Baltimore, and a gastroenterology fellowship at the Massachusetts General Hospital and Harvard Medical School in Boston. He subsequently pursued additional advanced therapeutic endoscopic fellowship training at the Massachusetts General Hospital and the Brigham and Women’s Hospital in Boston. After his fellowship, he was recruited to UCLA Medical Center in Los Angeles where he developed the largest endoscopic ultrasound program in California and became a founding member of the UCLA Center for Pancreatic Diseases. He was later recruited to lead the Yale Center for Pancreatic Diseases at Yale School of Medicine and the Yale New Haven Hospital, while also joining the existing Yale Interventional Endoscopy Program.

Dr. Farrell is board certified in internal medicine, gastroenterology, and clinical pharmacology. He currently serves on the medical advisory board for PANCAN, the Pancreas Cancer Action Network, as well as the NIH/NCI Pancreas Cancer Task Force. He is the author of numerous publications and maintains a vigorous clinical practice focused on all aspects of interventional endoscopy, gastrointestinal cancer, and pancreatic diseases. He is an internationally recognized expert in pancreatic disease treatment and research. In addition to his clinical work on the endoscopic evaluation of autoimmune pancreatitis and pancreatic cysts, and endoscopic ultrasound delivery of gene therapy for pancreatic cancer, he is also known for his development of personalized therapy approaches for pancreatic cancer and early detection biomarkers for pancreatic cancer.

Jill Lacy, MD
Associate Professor
Department of Medicine
Yale School of Medicine
New Haven, Connecticut

Dr. Jill Lacy received her medical degree from Yale School of Medicine She completed an internal medicine residency, chief residency, and oncology fellowship at Yale-New Haven Hospital and Yale School of Medicine. Dr. Lacy is currently an associate professor in the Department of Medicine at Yale School of Medicine in New Haven, Connecticut.

Dr. Lacy is board certified in internal medicine and medical oncology. She is director of the hematology-oncology fellowship program, leader of the GI oncology tumor board, as well as chair of ASCO Diversity in Oncology Initiative advisory and review committee. Dr. Lacy is on the editorial board of Journal of Cancer Therapy and is a reviewer for The Cancer Journal, Blood, New England Journal of Medicine, Clinical Cancer Research, and the Journal of Hematology and Oncology, among others. She has written various peer-reviewed articles and book chapters on lymphoma and metastatic cancer.

Anil K. Rustgi, MD
T. Grier Miller Professor of Medicine and Genetics
Chief, Division of Gastroenterology
University of Pennsylvania, School of Medicine
Philadelphia, Pennsylvania

Dr. Anil K. Rustgi received his medical degree from Duke University Medical School and completed his medical internship and residency at Beth Israel Hospital of Harvard University, and also served as chief medical resident. He then completed his gastroenterology fellowship at Massachusetts General Hospital (MGH) of Harvard Medical School. Dr. Rustgi is the chief of gastroenterology and the T. Grier Miller Professor of Medicine and Genetics as well as director of the Digestive Diseases and Liver Clinical Center at the University of Pennsylvania.

Dr. Rustgi is a diplomate in gastroenterology, American Board of Internal Medicine. He is on the scientific advisory board of the National Pancreas Foundation, Caring for Carcinoid Foundation, and PanCAN, and is past-president of the American Gastroenterology Association. Dr. Rustgi is a reviewer for numerous peer-reviewed journals including Science, Cancer Cell, Journal of Clinical Investigation, New England Journal of Medicine, Gastroenterology, Annals of Internal Medicine, Lancet, American Journal of Medicine, and Cancer Research, just to name a few. In addition, he is associate editor of Cancer Research, Cancer Biology & Therapy, and GI Cancer. His primary research interest is in GI cancer biology and genetics related to oral-esophageal cancer, pancreatic cancer, and colon cancer, with a particular focus in tumor microenvironment.

Accreditation

MediCom WOrldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-017-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Drs. James Farrell, Jill Lacy, and Anil Rustgi have disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Farrell, Lacy, and Rustgi have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Farrell and Dr. Rustgi have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Dr. Lacy has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@partnersinpancreaticcancer.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Celgene Corporation and Aduro BioTech.

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved